Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The varicella vaccine developed by Jiangsu gdk Biotechnology is a prophylactic agent designed to prevent chickenpox (varicella) caused by the varicella-zoster virus (VZV). It works by inducing a protective immune response, typically through the use of a live-attenuated virus, which stimulates the production of VZV-specific antibodies and cell-mediated immunity. This vaccine is part of the product portfolio of Jiangsu gdk Biotechnology, a Chinese vaccine manufacturer that also produces quadrivalent influenza vaccines. The vaccine is intended for use in children and susceptible adults to provide long-term protection against primary VZV infection and its associated complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on varicella vaccine (Jiangsu gdk Biotechnology).